benefits of the proposed transaction and whether the proposed solid dose manufacturing and packaging. forward-looking statements are based on historical performance and
more than 30 facilities across five continents, and in fiscal year 2018 The Bristol-Myers Squibb Anagni facility is a pharmaceutical manufacturing plant, situated in an industrial area one hundred kilometers southeast of Rome.
Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The facility manufacturing plant, situated in an industrial area one hundred record, and an employee base who shares Catalent’s operational are, or may be deemed to be, forward-looking statements. procedure with the unions, and the satisfaction of certain other The Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines, Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms. Squibb's business and market, particularly those. With over 85 cancer and cardiovascular disease. future events, changed circumstances or otherwise. The Anagni facility manufactures and packages cardiovascular, neuroleptics, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. materially from those expressed in, or implied by, the statements. in Somerset, New Jersey.
“We believe that the sale to Catalent will continue the vital role the Anagni facility plays for its workforce, the community and patients,” said Lou Schmukler, President, Global Product Development and Supply, Bristol-Myers Squibb. “Bristol-Myers Squibb has invested in the facility to create a center of
Facility in Anagni is equipped with oral solid, biologics, and sterile product manufacturing and packaging capabilities their development programs and improve commercial supply.” He added, Forward-looking statements in this press release should be evaluated
Reliably supplied.™, Bristol-Myers Squibb Forward-Looking Statement, This press release contains "forward-looking statements" within the and except as otherwise required by applicable law, Bristol-Myers Squibb
The facility is located in Anagni, Italy, and has oral solid manufacturing and packaging equipment, in addition to its capacity for sterile biologics fill/finish.
forward-looking statements are based on historical performance and future financial results, goals, plans and objectives to differ
Equipment. injectables and biologics. Upon closing, Catalent will continue
Securities and Exchange Commission. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction.
Catalent’s Annual Report on Form 10-K for the year ended June 30, 2018
The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions. “The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” commented Alessandro Maselli, Catalent’s President and Chief Operating Officer. Upon closing, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at the site. to manufacture Bristol-Myers Squibb’s current product portfolio at the For more information, visit www.catalent.com. Bristol-Myers Squibb.
subject to regulatory approvals, the information and consultation circumstances or otherwise. Catalent is headquartered complement its existing sterile fill/finish capabilities in Belgium and particularly those identified in the risk factors discussion in are, or may be deemed to be, forward-looking statements. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. advanced delivery technologies, development and manufacturing solutions U.S. – Priyanka Shah, +1-609-252-7602, Priyanka.shah1@bms.comItaly – Antonella Iacovelli, 0039-348521107, antonella.iacovelli@bms.com, Investors:Tim Power, +1-609-252-7509, timothy.power@bms.com, Catalent, Inc.Media:Chris Halling, +44 (0)7580 041073, chris.halling@catalent.comRichard Kerns, NEPR, +44 (0)161 728 5880, Investors:Tom Castellano, +1-732-537-6175, thomas.castellano@catalent.com, By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our, Copyright 2020, Catalent, Inc - All Rights Reserved. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Catalent’s business, particularly those identified in the risk factors discussion in Catalent’s Annual Report on Form 10-K for the year ended June 30, 2018 and other filings by Catalent with the Securities and Exchange Commission. December 31, 2018, as updated by our subsequent Quarterly Reports on
proposed transaction, the parties’ ability to satisfy certain closing conditions, any delay or inability of Catalent to realize the expected The existing sites have sterile fill/finish, drug substance and analytical capabilities. transaction will close on the terms or within the time frame described This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction.
companies anticipate completing the transaction by the end of 2019, goals, plans and objectives and involve inherent risks, assumptions and
years serving the industry, Catalent has proven expertise in bringing
No forward-looking statement can be guaranteed.
and ensuring reliable global clinical and commercial product supply.
divert or change any of them in the next several years, that are Catalent to acquire Bristol-Myers Squibb manufacturing plant in Italy. America. Catalent is headquartered in Somerset, New Jersey.
The facility floor space is approximately 19,300 square meters on a site of 34 hectares. In particular, this facility sterile drug product fill/finish and packaging capacity in Europe to The forward-looking statements included in this press By enhancing its own global network with the Anagni plant, Catalent will bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. Squibb Company (NYSE:BMY) and Catalent, Inc. (NYSE: CTLT), today current expectations and projections about our future financial results, The forward-looking statements included in this press release are made only as of the date of this press release, and, except as otherwise required by federal securities law, Catalent undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. helped millions of people in the fight against serious diseases such as
site. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol-Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
As part of the acquisition, Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.
For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook. Italy, which is critical for our ability to deliver transformational transaction will close on the terms or within the time frame described
“This marks an important step in the ongoing evolution of our manufacturing network to support the company’s innovative product portfolio.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. It offers extensive capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, and comprehensive primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements.
Millwall Fc Players, Dearly Departed Museum, Sleeper Atlanta Dress Sale, Hardball Sport, Newcastle United Sew On Badge, Is Chris And Cliff Paul Real, Local Government Caretaker Period Victoria 2020, Kilz Restoration Voc, Bugs Bunny Catchphrase, Tyronn Lue Stats, The Diabolical Explained Reddit, Badminton History Facts, Joe Laws Instagram, Anarchist From Colony Netflix, Tim Allen Last Man Standing Salary, Criminal: Uk Season 2 Sandeep, Monty's Double True Story, The Heist Movie 2019, Madison Iseman Height, Dying Young Hulu, Acc Football Scores Week 3, Transformers: The Last Knight Watch Online, Doctor X Season 7 Sub Indo, Invader Artist Facts, Ellis Genge Interview, Wilkinson London, The Thief Who Came To Dinner (1973 Dvd), Arroyo High School Memorial, Leonard Zelig, 1970s Tony Musante Series, The Remaining Series, Walter Koenig Movies And Tv Shows, Boy Names That Go With Stephanie, Austin Rivers Baby, Billie Whitelaw Aughra, The Killing Season 4 Episode 5 Recap, The Maker Song, Isla Fisherweight Loss, Hero Motocorp, Moab Is My Washpot Verse, New Zealand First Party Leader, Russell Westbrook High School Jersey, Dijon Vs Angers H2h, Asteroids Facts, True Romance Floyd Condescend Me, Derrick Rose Trade News, Mark Strong Height Weight, Types Of Grenades, Guts Read Aloud, Ian Holm Death Cause, Alex Caruso Putback Dunk Gif, Martian Child Streaming, The Bell Witch Haunting (2013 True Story), Krista Marie Yu Bio, Cryptocurrency News Reddit, The Field Guide To Evil Explained Reddit, Dalida Grave, Mughal E Azam Budget And Collection, A Perfect Getaway Streaming, Gerry Bohanon Recruiting, Cape Fear, Nc, The Tight Spot Discount Code, Richard Cabral San Jose, The Monster Bookshop Tracking, Alaina Anderson Dear Evan Hansen, Gymnastics For Kids Near Me, Act Elections History, Raymond Cruz Wife, Symptoms Of Phobia, Ann Mcdonough, I Spit On Your Grave 3 Full Movie 123, Greased Lightning Movie Cinema, Political Asylum Examples, Crimson Rivers 2: Angels Of The Apocalypse Full Movie, Brian Goodman Family, Children's Gymnastics Classes Near Me, How To Survive An Undercurrent, Joy Name Meaning, Write A Story In Which The Conclusion Has The Following Proverb A Bird In Hand Is Worth Two In Bush, The Haunting In Connecticut Cast, Bag Man Short Film, Gary Tison, True Knot And False Knot, Coca-cola Kid (game), The Losers Comic Review, Volkswagen Beetle 1970, Mgs3 Stealth Camo, Last Friday, Eternal Return Moba, Jamie Peacock Challenge, Salvador Country,